Authors
Latest:
Hereditary vs Familial Pancreatic Cancer: Associated Genetic Syndromes and Clinical PerspectivePancreatic ductal adenocarcinoma is a disease marked by high rates of mortality, with only about 7% of patients surviving 5 years after diagnosis. Here, the authors present a demonstrative case and review the available data on hereditary and familial PDAC.
Latest:
Unmet Needs and Future Directions for GPRC5D Bispecific TherapyPanelists discuss how unmet needs and future directions for GPRC5D bispecific therapy include improving accessibility, managing long-term safety, and exploring combination strategies to enhance treatment efficacy.
Latest:
Use of Immunotherapy in Patients With Cancer During the COVID-19 PandemicThis article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.
Latest:
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabRituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
Latest:
Collaborative Education for CAR T-Cell TherapyThe panel concludes its discussion with insights on practices for educating health care teams on CAR T-cell therapy administration, highlighting the evolving role of advanced practice providers.
Latest:
Prospective Data Establishing the Clinical Utility of Testing All Biomarkers in Advanced Bladder Cancer is Still Needed, Says ExpertWith the increasing clinical use of circulating tumor DNA biomarker testing among community urologists, an expert from Tisch Cancer Institute at Mount Sinai in New York City suggests that more prospective data are needed to make the best decisions among patients with bladder cancer.
Latest:
CANCER TREATMENT CENTERS OF AMERICA RECEIVES 2021 PRESS GANEY GUARDIAN OF EXCELLENCE AWARD®Comprehensive cancer centers in Chicago and Atlanta earn national distinction as top performers in patient experience.
Latest:
Clinical Trials in Progress: ROADS TrialPhase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with GammaTile for Treatment of Newly Diagnosed Metastatic Brain Tumors (ROADS; NCT04365374)
Latest:
A 65-Year-Old Man With Back Pain and Imaging Findings of Spinal Cord CompressionMehmet S. Copur, MD, and colleagues examine the case of a 65-year-old who presented with back pain and a large T8 spinal mass, leading to a diagnosis of multiple myeloma with spinal cord compromise.
Latest:
Combatting Stigmatization to Increase Lung Cancer Screening AccessLisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, discusses how LungTalk, a health communication and decision support tool, may spread awareness and knowledge surrounding lung cancer screening.
Latest:
Multiple Myeloma: Unmet Needs and Future PerspectivesClosing out their discussion on the management of multiple myeloma, experts from the Moffit Cancer Center highlight key unmet needs and future directions in care.
Latest:
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast CancerPatients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
Latest:
Early Recurrence Post-Pembrolizumab Inspires Zanzalitinib Trial in ccRCCZanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
Latest:
Future Perspectives and Unmet Needs in Multiple MyelomaThe expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.
Latest:
Cevostamab Combo Shows Enduring Responses in R/R Multiple MyelomaAdditional time is necessary to confirm the depth and durability of responses observed in the phase 1 CAMMA 1 study.
Latest:
Physician Assistant Perspectives: When to Consider Tazemetostat in R/R FLA panelist discusses how tazemetostat offers a convenient, mutation-independent oral option for third-line follicular lymphoma treatment, balancing efficacy and tolerability while addressing patient lifestyle and financial considerations in an era of advanced therapies like CAR T-cell and bispecific antibodies.
Latest:
Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical BenefitPanelists discuss how effective management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in complex extensive-stage small cell lung cancer (ES-SCLC) cases treated with tarlatamab enables patients to continue therapy and achieve meaningful clinical benefit despite early toxicities.
